| 1 |
33970096 | Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report. | 2021 May |
1 |
| 2 |
31714594 | Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. | 2020 Feb 15 |
1 |
| 3 |
33138032 | RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status. | 2020 Oct 29 |
1 |
| 4 |
29500400 | Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. | 2018 Mar 2 |
1 |
| 5 |
28759753 | Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib. | 2017 Oct |
7 |
| 6 |
25888415 | Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. | 2015 Mar 7 |
2 |
| 7 |
24625059 | Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. | 2014 Mar 13 |
1 |
| 8 |
24675890 | Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manner. | 2014 |
1 |
| 9 |
23239809 | Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. | 2013 Feb |
1 |
| 10 |
24222661 | Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. | 2013 Dec |
1 |
| 11 |
20049732 | Converting cancer mutations into therapeutic opportunities. | 2009 Sep |
2 |